Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of “Hold” by Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR) have received a consensus recommendation of “Hold” from the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $24.50.

XNCR has been the subject of a number of recent analyst reports. Barclays increased their target price on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Wall Street Zen cut shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Friday, March 27th. Zacks Research cut shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. increased their target price on shares of Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Monday, May 11th.

Institutional Trading of Xencor

Several large investors have recently made changes to their positions in the business. Primecap Management Co. CA increased its position in Xencor by 1.4% in the 3rd quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company’s stock valued at $125,218,000 after acquiring an additional 147,700 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Xencor by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock worth $109,703,000 after acquiring an additional 61,692 shares during the last quarter. BVF Inc. IL raised its stake in shares of Xencor by 160.3% in the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after acquiring an additional 4,393,579 shares during the last quarter. RTW Investments LP raised its stake in shares of Xencor by 8.9% in the fourth quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock worth $103,763,000 after acquiring an additional 556,407 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Xencor by 22.7% in the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock worth $69,006,000 after acquiring an additional 833,423 shares during the last quarter.

Xencor Price Performance

Shares of Xencor stock opened at $14.45 on Thursday. The firm has a market capitalization of $1.07 billion, a PE ratio of -6.31 and a beta of 0.92. The company’s fifty day moving average price is $12.23 and its two-hundred day moving average price is $12.86. Xencor has a 52-week low of $6.92 and a 52-week high of $18.69.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The business had revenue of $4.52 million during the quarter, compared to the consensus estimate of $27.86 million. Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The company’s quarterly revenue was down 86.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.66) EPS. Analysts predict that Xencor will post -3.84 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.